C84.A7 ICD-10-CM Code: Cutaneous T-cell lymphoma, unspecified, spleen
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C84.A7
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceCutaneous T-cell lymphoma, unspecified, spleen
A cancer of T cells that primarily affects the skin with involvement of the spleen, an organ that filters blood and stores immune cells.

Buddy Insight
Cutaneous T-cell lymphoma with splenic involvement indicates advanced systemic disease that has spread beyond the skin.
CMS-HCC V28
MappedHCC 20
RAF 0.0
CMS-HCC V24
MappedHCC 10
RAF 0.675
ACA/HHS
00
RAF 0
ESRD/PACE
MappedHCC 10
RAF 0.0
RXHCC
MappedHCC 21
RAF 0.0
Code Trumping
Basket needed
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C84.A7 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C84.A7 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C84.A7 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C84.A7 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C84.A7 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C84.A7 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C84.A7 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is C84.A7 an HCC code?
Yes. C84.A7 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C84.A7
For C84.A7to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C84.A7 during that encounter, not just copy-forwarded from a problem list.
What This Code Means
C84.A7 is the ICD-10-CM diagnosis code for cutaneous t-cell lymphoma, unspecified, spleen. A cancer of T cells that primarily affects the skin with involvement of the spleen, an organ that filters blood and stores immune cells. C84.A7 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C84.A7 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C84.A7 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Splenic involvement indicates systemic disease beyond skin manifestations. Because C84.A7 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C84.A7 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Splenic involvement indicates systemic disease beyond skin manifestations
- •Verify imaging or pathology documentation confirms spleen involvement
Clinical Significance
Cutaneous T-cell lymphoma with splenic involvement indicates advanced systemic disease that has spread beyond the skin. Splenic involvement significantly impacts staging, treatment decisions, and prognosis, often requiring systemic chemotherapy rather than skin-directed therapy alone. This represents a higher disease burden requiring intensive management.
Documentation Requirements
- ✓Pathology or imaging confirmation of splenic involvement (CT, PET scan, or splenectomy findings)
- ✓Documentation that the primary lymphoma is cutaneous T-cell type confirmed by skin biopsy with immunophenotyping
- ✓Current disease staging (typically stage IV with visceral organ involvement)
- ✓Treatment plan reflecting systemic disease (chemotherapy, targeted therapy, stem cell transplant consideration)
Commonly Confused Codes
- •C84.A0 (Cutaneous T-cell lymphoma, unspecified site) — Use C84.A7 when spleen is specifically documented as involved
- •C84.Z7 (Other mature T/NK-cell lymphomas, spleen) — Use C84.A7 for cutaneous T-cell lymphoma specifically; C84.Z7 is for other T/NK-cell subtypes
- •C84.A8 (Cutaneous T-cell lymphoma, lymph nodes of multiple sites) — Splenic involvement is coded separately from lymph node involvement